evenfolio

Healthcare · NSE: VIYASH

Viyash Scientific

Q2 FY27 earnings highlights, from the results presentation

Price as of 16 Nov 2026
236.38−7.42%

Q2 FY27 · From the investor presentation

Read the filing on NSEFiling

128​KLAPI reactor capacity · APIsSlides · p. 14
M.Cap
₹10,439Cr
P/E
44.9×
1Y return
+3.19%
From 52W high
−20.7%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue988424+133.0%946+4.4%
EBITDA16556+196.2%178-7.5%
EBITDA margin16.7%13.1%+357 bps18.9%-215 bps
One-off items—-2———
PBTProfit before tax11827+333.3%112+4.7%
Net profit7615+416.8%66+15.6%
EPS (₹)1.690.58+191.4%1.47+15.0%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

In short

  1. 01Q2 FY27 revenue was Rs 9,879 Mn, up 16.2% YoY; H1 revenue Rs 19,343 Mn, up 17.8%.
  2. 02H1 FY27 PAT was INR 164 Cr, up about 50%; adjusted PAT with normalized ESOP cost INR 204 Cr.
  3. 03Q2 EBITDA before ESOP cost was Rs 2,077 Mn at a 21.0% margin, against 22.1% a year earlier.
  4. 04Acquisition of BioForLife in Italy was completed on 1 October 2026.
  5. 05Capex has started on a companion animal tablet facility at Ambernath; slide shows Q1 FY28.
  6. 06A new 128 KL API block at Nalgonda has received all approvals.
  7. 07A new oncology finished-dosage R&D centre is being built in Hyderabad.
  8. 08Net debt stood at Rs 261 Mn.

Capex

Human Health: Building an oncology platform from API to finished dosage, with new R&D centre

Slides · p. 12
“Building an end-to-end oncology platform, from API to finished dosage”

Companion animals: Capex initiated for new companion animal tablet facility at Ambernath

Slides · p. 13
“Capex initiated for new tablet facility Expected commissioning & start of production”

Companion animals: Ambernath companion animal facility: commissioning and start of production expected Q1 FY28

Slides · p. 13
“Commencement Q1 FY28 Capex initiated for new tablet facility Expected commissioning & start of production”

Company investing in new oncology capabilities

Slides · Managing Director and Group CEO · p. 3
“We are also investing in new oncology capabilities, in-house”

Companion animals: Ambernath plant to give in-house manufacturing for companion animal pipeline

Slides · p. 13
“Day-1 launch readiness: In-house manufacturing for our companion animal pipeline”

Segments

Formulations: Formulations Q2 FY27 sales Rs 5,587 Mn, up 19% YoY; H1 up 26%

Slides · p. 10
“Formulations 5,587 4,687 19% 5,547 1% 11,134 8,858 26%”

Europe: Europe Q2 FY27 sales Rs 1,864 Mn, up 22% YoY

Slides · p. 10
“Europe 1,864 1,532 22% 1,847 1% 3,711 3,211 16%”

Emerging Markets: Emerging Markets Q2 FY27 sales Rs 2,030 Mn, up 39% YoY

Slides · p. 10
“Emerging Markets 2,030 1,457 39% 2,008 1% 4,038 2,898 39%”

India: India Q2 FY27 sales Rs 504 Mn, up 39% YoY; H1 up 49%

Slides · p. 10
“India 504 362 39% 430 17% 934 625 49%”

USA: USA Q2 FY27 sales Rs 1,189 Mn, down 11% YoY and down 6% QoQ

Slides · p. 10
“USA 1,189 1,337 -11% 1,262 -6% 2,451 2,124 15%”

Demand

APIs: New API block adds capacity to support rising demand for select APIs

Slides · p. 14
“New block adds capacity to support rising demand”

Margins and costs

Q2 FY27 EBITDA margin 21.0% vs 22.1% a year ago; H1 21.3% vs 19.3%

Slides · p. 8
“% EBITDA 21.0% 22.1% 21.6% 21.3% 19.3%”

Q2 FY27 gross margin 53.7% vs 55.5% a year ago and 54.1% in Q1

Slides · p. 8
“% Gross margin 53.7% 55.5% 54.1% 53.9% 53.8%”

Q2 FY27 ESOP cost Rs 421 Mn vs Rs 100 Mn a year ago; H1 Rs 667 Mn

Slides · p. 8
“ESOP cost (421) (100) (246) (667) (230)”

Normalized annual ESOP cost assumed at INR 25 Cr

Slides · p. 3
“Notes: * Assuming normalized annual ESOP cost at INR 25 Cr”

Q2 FY27 depreciation Rs 453 Mn vs Rs 591 Mn a year ago

Slides · p. 8
“Depreciation (453) (591) (618) (1,071) (1,147)”

Debt and working capital

Net debt Rs 261 Mn at end of Q2 FY27

Slides · p. 5
“Million Million Net Debt- ₹ 261 Mn”

Q2 FY27 finance cost Rs 137 Mn vs Rs 175 Mn a year ago; H1 Rs 262 Mn

Slides · p. 8
“Finance Cost (137) (175) (125) (262) (379)”

Net debt was Rs 861 Mn in Q1 FY27

Slides · p. 6
“Net Debt - ₹ 861 Mn”

Net debt was Rs 4,095 Mn in H1 FY26

Slides · p. 5
“Net Debt - ₹ 4,095 Mn”

Net debt to LTM EBITDA at 0.0x in Q2 FY27

Slides · p. 6
“₹9,879 ₹2,077 21.0% 0.0x”

Acquisitions and new business

Companion animals: Acquisition of BioForLife in Italy completed on 1 October 2026

Slides · p. 11
“Completion of Acquisition: 1 October 2026”

Companion animals: BioForLife sales force has 85% vet clinic coverage in Italy

Slides · p. 11
“Italy; salesforce has 85% vet”

Companion animals: BioForLife share purchase agreement signed on 21 July 2026

Slides · p. 11
“Execution of SPA: 21 July 2026”

One-offs

Prior-year one-off was a provision for customer claim on earlier shipments

Slides · p. 10
“*Adjustment on account of hyperinflation in Turkey as per Ind AS 29 # Provision for customer claim on shipments in prior years”

Other

Q2 FY27 revenue Rs 9,879 Mn, up 16.2% YoY; H1 Rs 19,343 Mn, up 17.8%

Slides · p. 8
“Revenue from Operations 9,879 8,503 16.2% 9,464 4.4% 19,343 16,419 17.8%”

H1 FY27 PAT at INR 164 Cr, up about 50% from last year

Slides · Managing Director and Group CEO · p. 3
“profit after tax (PAT) at INR 164 Cr, up ~50% from last year. H1 adjusted PAT with normalized”

H1 adjusted PAT with normalized ESOP cost is INR 204 Cr

Slides · Managing Director and Group CEO · p. 3
“ESOP cost is INR 204 Cr*. The completion of acquisition of BioForLife in Italy strengthens our”

Q2 FY27 EBITDA before ESOP cost Rs 2,077 Mn, up 10.3%; H1 Rs 4,124 Mn, up 29.9%

Slides · p. 8
“EBITDA¹ 2,077 1,883 10.3% 2,047 1.4% 4,124 3,176 29.9%”

Q2 FY27 earnings after tax Rs 847 Mn, up 16.1%; H1 Rs 1,639 Mn, up 49.4%

Slides · p. 8
“Earnings After Tax 847 729 16.1% 793 6.8% 1,639 1,098 49.4%”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools